Clinical trials: Tace
Hepatocellular Carcinoma
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
Hepatocellular carcinoma (HCC) patients is a common disease in the East Asia. Although resection was recommend for early stage (BCLC A stage) patients according to the BCLC (Barcelona clinical liver cancer) system, increasing…
- Trial name
- NCT04777942
- Testing
- neo-TACE-HAIC+Surgery, Surgery alone
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Sun Yat-sen University
Uveal Melanoma
Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis
Characterisation of effect of SIRT and DSM-TACE as local treatment options for liver metastases in patients with advanced uveal melanoma with respect to progression-free survival and exploratory comparison of secondary endpoints…
- Trial name
- SirTac (NCT02936388)
- Testing
- SIRT, DSM-TACE
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Charite University, Berlin, Germany
Unresectable Hepatocellular Carcinoma
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
This is a multicenter, retrospective, observational cohort study to describe the effectiveness and safety of Atezo+Bev plus Transarterial Chemoembolization (TACE) among adult patients with unresectable hepatocellular carcinoma…
- Trial name
- NCT06503250
- Testing
- Atezolizumab, Bevacizumab, Transarterial Chemoembolization
- Where
- 5 sites in China
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with…
- Trial name
- NCT06607120
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
DEB-TACE for Hepatocellular Carcinoma
Patients enrolled in this study have been diagnosed with hepatocellular carcinoma (HCC) and are scheduled to have a procedure called drug-eluting bead trans-arterial chemoembolization (DEB-TACE).
- Trial name
- QED (NCT02748161)
- Testing
- DEB-TACE
- Where
- 11 sites in United States
- Volunteers
- 170 people
- Sponsor
- Surefire Medical, Inc.
Cholangiocarcinoma Non-resectable
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of Drug-eluting Beads-transarterial chemoembolization (DEB-TACE)…
- Trial name
- CCGLC-009 (NCT06194695)
- Testing
- drug eluting beads-transcatheter arterial chemoembolization, envatinib plus anti-PD(L)1
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ze-yang Ding, MD
Advanced Hepatocellular Carcinoma
Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
This study is a single-center, open, single-arm, phase II clinical trial. Eligible HCC patients, after signing informed consent, will receive TACE treatment.
- Trial name
- CISLD-12 (NCT05213221)
- Testing
- Envafolimab, TACE, Lenvatinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma Non-resectable
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
Aim of the study is to evaluate the efficacy of up-front atezolizumab/ bevacizumab (Atezo/Bev) followed by on-demand selective transarterial chemoembolization (sdTACE) and of initial synchronous treatment with TACE and Atezo/Bev…
- Trial name
- DEMAND (NCT04224636)
- Testing
- Atezolizumab Injection, Bevacizumab Injection
- Where
- 7 sites in Germany
- Volunteers
- 106 people
- Sponsor
- Ludwig-Maximilians - University of Munich
HCC, Portal Vein Tumor Thrombosis
ISP-TACE Versus TACE for HCC With PVTT
For patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT), the survival benefit of transarterial chemoembolization (TACE) remains modest.
- Trial name
- NCT03108248
- Testing
- ethiodized oil; doxorubicin;Gelfoam;, stent; idoine-125
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Zhongda Hospital
Carcinoma, Hepatocellular
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Primary Objective: To compare the efficacy of TACE vs. CyberKnife SBRT in the treatment of locally recurrent HCC after initial TACE. Secondary Objectives: 1. To determine the progression-free survival of TACE vs.
- Trial name
- NCT01327521
- Testing
- CyberKnife, TACE, CT Contrast
- Where
- United States
- Sponsor
- Albert Koong
Hepatocellular Carcinoma
Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma
A multicentric, open-label, single-arm prospective study to assess the efficacy and safety of tislelizumab combined with TACE as first-line treatment in patients with unresectable BCLC stage C HCC.
- Trial name
- NCT04652492
- Testing
- Tislelizumab in combination with cTACE
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Zhongda Hospital
HCC - Hepatocellular Carcinoma
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
The goal of this clinical trial is to evaluate the efficacy and safety of combining endovascular denervation (EDN) with transarterial chemoembolization/ hepatic arterial infusion chemotherapy (TACE/HAIC) plus second-line…
- Trial name
- NCT07187284
- Testing
- EDN combined with TACE/HAIC and Immuno-Targeted Therapy, TACE/HAIC plus Immuno-Targeted Therapy
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhongda Hospital
Hepatocellular Carcinoma
Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC
A primary hepatocellular carcinoma (HCC) is generally regarded as unresectable if the future liver remnant (FLR)≤40％ of total liver volume in patient with underlying liver disease, such as hepatitis B.
- Trial name
- TACEPVE (NCT00834158)
- Testing
- TACE, PVE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome…
- Trial name
- NCT04712643
- Testing
- Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE)
- Where
- 40 sites in China, Japan
- Volunteers
- 342 people
- Sponsor
- Hoffmann-La Roche
Precision Cells, Transcatheter Arterial Chemoembolization
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cells Combined With TACE in Advanced Liver Cancer.
- Conditions
- Precision Cells, Transcatheter Arterial Chemoembolization, Advanced Liver Cancer
- Trial name
- NCT02862613
- Testing
- TACE, Precision Cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai International Medical Center
Hepatocellular Carcinoma
Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC
This trial is a multi-center, phase III, randomized (1:1) clinical trial. The aim is to explore the efficacy and safety of Sorafenib combined with transarterial chemoembolization as adjuvant treatment for resectable advanced…
- Trial name
- SOURCE (NCT04143191)
- Testing
- Sorafenib, Transarterial chemoembolization
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Sun Yat-sen University
Nausea, Vomiting
Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE
Observation on acupoint electric stimulation combined with tropisetron in preventing and treating nausea and vomiting and improving the patient's appetite after TACE for primary or metastatic liver cancer patients.
- Conditions
- Nausea, Vomiting, Metastatic Liver Cancer
- Trial name
- NCT01895010
- Testing
- acupoint electric stimulation, tropisetron
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Fudan University
Liver Metastasis Colon Cancer
TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens
Liver metastasis is the main reason that affects the survival rates of patients with colorectal cancer (CRLM), and is also the main cause of death of those patients.
- Trial name
- DREAM (NCT06071052)
- Testing
- TACE and HAIC Combined With Regorafenib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
HCC
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
Major objectives To evaluate the efficacy of lparomlimab and Tuvonralimab injection (QL1706, an Anti-PD-1/ CTLA-4 Combined Antibody) in combination with TACE and lenvatinib as second-line therapy in patients with unresectable…
- Trial name
- NCT07099274
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Circulating Tumor Cell;, Hepatocellular Carcinoma
Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence
Circulating tumour cell (CTC) count could reflect the effect of postoperative transarterial chemoembolization (TACE) on hepatocellular carcinoma (HCC) recurrence.
- Trial name
- NCT02032368
- Testing
- transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Guangdong Provincial People's Hospital